This is supported by recent studies describing the ability of the GR antagonist RU-486 to potentiate the antitumor efficacy of chemotherapeutics in triple-negative breast cancer (paclitaxel; Skor et al. 2013) and cervical cancer (cisplatin; Jurado et al. 2009). This evidence concerns the gene NR3C1 and triple-negative breast carcinoma.